Crititech, Inc.

Shelby Clark

Michael Baltezor

Joseph S Farthing

Mark D Williams

Jacob M Sittenauer

Gere Dizerega

Aranza Barreda Abarca

Matthew McClorey

The disclosure provides particles of at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm.

Lapatinib particles and uses thereof

Compositions of particles having at least 95% by weight of niraparib and a specific surface area (SSA) of at least 5 m/g, methods for their use, and methods for their production are provided.

Niraparib particles and uses thereof

Compositions of particles having at least 95% by weight of rucaparib and a specific surface area (SSA) of at least 12 m/g, methods for their use, and methods for their production are provided.

Rucaparib particles and uses thereof

The present disclosure relates to ciprofloxacin polymorphs and their use in treating infections.

Growing community of inventors

Lawrence, KS, United States of America

Shelby Clark